Xarelto Attorneys at Bernstein Liebhard LLP Comment on Survey Detailing Cardiologists’ Attitude Towards New-Generation Blood Thinners

Share Article

While the surveyed physicians were pleased that new blood thinning options such as Xarelto are now available, there was concern about the lack of an antidote to reverse internal bleeding, a side effect that is also at issue in hundreds of Xarelto lawsuit filings.

Free Case Review
The results of this survey are notable, as hundreds of people are currently pursuing Xarelto lawsuits in U.S. courts that seek compensation for internal bleeding and other complications allegedly related to its use.

The Xarelto attorneys (http://www.xareltolawsuit2015.com/) at Bernstein Liebhard LLP note that a survey conducted this month by the Cardiovascular Institute of Philadelphia produced interesting results regarding the attitude of cardiologists towards new-generation blood thinners. According to the Philadelphia Inquirer, while the physicians were generally pleased that alternatives to warfarin are now available, they expressed concern that there is currently no approved antidote to reverse unwanted internal bleeding that sometimes occurs with Xarelto and other anticoagulants. Warfarin bleeding, by contrast, can be stopped via an injection of vitamin K.*

“The results of this survey are notable, as hundreds of people are currently pursuing Xarelto lawsuits in U.S. courts that seek compensation for internal bleeding and other complications allegedly related to its use. These claims also raise questions about the lack of a reversal agent for Xarelto bleeding. This issue is certainly one that should be discussed with patients before the drug is prescribed,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently representing a number of clients who have filed Xarelto lawsuits, and continues to offer free, no-obligation legal reviews to individuals who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.

Xarelto Litigation
Xarelto is a new -generation blood thinner that was first approved by the U.S. Food & Drug Administration in 2011. The medication is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.** During its first full year on the market, Xarelto was named in 2,081 adverse event reports submitted to the FDA, including at least 151 deaths. Warfarin, which has been in use since the 1950s, was named in only 861 adverse event reports, including 56 fatalities.***

Court documents indicate that more than 200 Xarelto lawsuits are currently pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, all of which put forth similar allegations regarding the drug’s association with uncontrollable bleeding, hemorrhagic stroke, deep vein thrombosis, pulmonary embolism, and other life-threatening complications. Among other things, plaintiffs assert that the manufacturers of Xarelto wrongly marketed the drug as superior to warfarin, given the lack of an approved antidote to stop internal bleeding. In Re: Xarelto Products Liability Litigation, No. 2592)

Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to take legal action against the drug’s manufacturers. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.

*philly.com/philly/health/hearthealth/20150215_Cardiologists__concerns__Abnormal_heart_rhythm__blood_thinners__and_statins.html, Philadelphia Inquirer, February 15, 2015
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
***http://www.ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website